Kilitch Drugs announces 1:1 bonus issue, Q3 results

Revenue declinedResults View source PDF Explain this filing

KILITCH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.6%Reaction day

₹181.50

prior close

₹180.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-8.1% vs market

Pharmaceuticals peers, median of 157sector-0.6%-8.0% vs sector

On the reaction day the stock moved 8.1 pts less than Nifty Microcap 250 and 8.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.1

10m

-1.8

15m

-2.5

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.6-0.5-8.1-0.6-8.0

Next day

-9.9-2.0-7.9-1.4-8.5

-12.1-2.7-9.4-2.1-10.0

-11.3-1.7-9.6-1.6-9.7

-8.8-1.4-7.4-1.6-7.2

-12.5-2.8-9.7-2.4-10.1

-10.5-2.8-7.6-2.9-7.6

15d

-11.6-8.4-3.2-6.3-5.2

-9.7-9.1-0.6-6.5-3.2

-31.6-4.0-27.5-3.3-28.2

-19.0+2.6-21.6+0.9-19.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved 1:1 bonus issue (1 free share for every 1 held), subject to shareholder approval at EGM on March 13, 2026. Pre-bonus shares: 1.74 crore; post-bonus: 3.49 crore. Bonus from free reserves or securities premium by April 10. Also Q3 FY26 results: standalone net sales Rs 4,467 lakh versus Rs 1,651 lakh YoY; standalone PAT Rs 489 lakh versus Rs 688 lakh. Authorized capital raised to Rs 40 crore.

Likely market impact

Bonus doubles share count but does not change company value. Watch for record date and ex-date announcements.